We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
  • Akero Initiates Phase 2b HARMONY Study of Efruxifermin for NASH americanpharmaceuticalreview
    March 01, 2021
    Akero Therapeutics has screened the first patients for its Phase 2b HARMONY study evaluating efruxifermin (EFX), the company's lead product candidate for the treatment of NASH.
  • Akero Expands NASH Trial to Include Cohort of Cirrhotic Patients americanpharmaceuticalreview
    January 19, 2020
  • Akero Announces Dosing of First Patient in NASH Study americanpharmaceuticalreview
    July 04, 2019
PharmaSources Customer Service